A Phase 2 interventional study of Finerenone (BAY94-8862) and Placebo in Heart Failure, sponsored by Bayer. Completed at 172 sites in 25 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-06.
Sponsored by Bayer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing finerenone in Heart Failure — 16 open to participants now, 17 under way, 8 of them phase 3. finerenone · Heart Failure.
Among the 23 studies testing finerenone in Heart Failure, this one is the 7th largest by enrollment, is one of 2 that started in 2013, is one of 5 in phase 2, and was the 3rd registered.
6,334 studies on the registry are indexed under Heart Failure; 1,392 are open to participants now.
Browse Heart Failure studies →16 of the 23 studies testing finerenone in Heart Failure are open now, in 12 countries. Recruiting first, the newest first:
Second Affiliated Hospital, Zhejiang University, School of Medicine · Sites in China
Ages 65+
Bayer · Sites in United States, Argentina, Austria and 20 more countries
Ages up to 18
Juntendo University · Sites in Japan
Ages 18+
Bayer · Sites in United States, Argentina, Austria and 20 more countries
Ages 6 mo–17 yrs
Colorado Prevention Center · Sites in United States, Argentina, Brazil and 11 more countries
Ages 18+
By country, each count listing its studies:
finerenone: first FDA approval 2021 (KERENDIA), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 966 Heart Failure studies recruiting now, 689 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,066 is above the median of 76 across 4,049 interventional studies indexed under Heart Failure.
Median enrollment 120 across the 23 interventional studies. Of the 6 that completed or were terminated, 2 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 23 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
47 studies in Heart Failure by Bayer: 6 open now, 7 under way, 2 of them phase 3. Of 40 finished, 9 (23%) have results posted.
Among the 47 studies in Heart Failure by Bayer, this one is the 2nd largest by enrollment of the 33 interventional ones that give a count, is one of 5 that started in 2013, is one of 18 in phase 2, and was the 8th registered.
Bayer’s Heart Failure studies by the year they started, since 2007.
5 of the studies testing finerenone in Heart Failure that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06024746Phase 3Colorado Prevention CenterA Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF) | 2027-11 |
| NCT06008197Phase 3Colorado Prevention CenterA Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients | 2027-11 |
| NCT06059664University of North Carolina, Chapel HillThe EFfect of FinErenone in Kidney TransplantiOn Recipients: The EFFEKTOR Study | 2027-03-31 |
| NCT07830940Assiut UniversityFinerenone and Cardiac Remodeling in HFpEF | 2027-09-25 |
| NCT07583173China National Center for Cardiovascular DiseasesEffect of Finerenone on Myocardial Fibrosis and Cardiac Function in HFmrEF/HFpEF Patients | 2027-10-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 23 studies testing finerenone in Heart Failure, from their registry updates:
Among Bayer’s 47 in Heart Failure:
This tab as a report to print or save as PDF → With an account.
To assess a new drug, BAY94-8862, given orally at different doses, to evaluate whether it was safe and can help the well-being of patients with worsening chronic heart failure and either type II diabetes with or without chronic kidney disease or kidney disease alone. These treatment doses were compared to eplerenone, another marketed drug approved to treat heart failure.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral - 2.5mg once daily (OD) for 30 days. Potential up-titration to 5mg OD after 30 days or 60 days. Treatment duration 90 days. Placebo OD for 90 days.
Drug: Finerenone (BAY94-8862) · Drug: Placebo
Oral - 5mg OD for 30 days. Potential up-titration to 10 mg OD after 30 days or 60 days. Treatment duration 90 days. Placebo OD for 90 days.
Drug: Finerenone (BAY94-8862) · Drug: Placebo
Oral - 7.5mg OD for 30 days. Potential up-titration to 15 mg OD after 30 days or 60 days. Treatment duration 90 days. Placebo OD for 90 days.
Drug: Finerenone (BAY94-8862) · Drug: Placebo
Oral - 10mg OD for 30 days. Potential up-titration to 20 mg OD after 30 days or 60 days. Treatment duration 90 days. Placebo OD for 90 days.
Drug: Finerenone (BAY94-8862) · Drug: Placebo
Oral - 15mg OD for 30 days. Potential up-titration to 20 mg OD after 30 days or 60 days. Treatment duration 90 days. Placebo OD for 90 days.
Drug: Finerenone (BAY94-8862) · Drug: Placebo
Oral - 25mg every other day (EOD). Potential up-titration to 25mg OD after 30 days and 50mg OD after 60 days.Placebo OD for 90 days.
Drug: Placebo · Drug: Inspra (eplerenone)
Percentage of Participants With a Relative Decrease in NT-proBNP of More Than 30% From Baseline to Day 90
N-terminal pro-B type natriuretic peptide (NT-proBNP) levels in the blood are used for screening, diagnosis of acute and chronic heart failure (CHF) and may be useful to establish prognosis in heart failure.
Time frame: Baseline and Day 90
Number of Participants With Death Due to Any Cause
Death due to any cause include cardiovascular (CV) death and Non-CV death. Non-CV death was classified by 2 subcategories: non-malignant causes and malignant causes.
Time frame: Day 30, Day 60, Day 90 and Follow-up (30 days post-last dose, assessed up to Day 120)
Number of Participants With Cardiovascular Hospitalization
Hospitalizations were defined as any unplanned admission to hospital, i.e. completion of hospital admission procedures and one overnight \[i.e. date change\] stay or until the death of subject occurred. Hospitalizations and deaths were classified by 2 primary categories: CV and non-CV. The pre-specified subcategories for CV hospitalizations were as follows: 1. Worsening heart failure, 2.Acute myocardial infarction, 3. Arrhythmia, 4.Transient ischemic attack and stroke, 5. Other CV hospitalizations.
Time frame: Day 30, Day 60, Day 90 and Follow-up (30 days post-last dose, assessed up to Day 120)
Number of Participants With Emergency Presentations for Worsening Chronic Heart Failure (WCHF)
Emergency presentations for WCHF were defined as newly developing signs and symptoms of WCHF after start of treatment with study drug, requiring an additional emergency presentation to hospital and IV treatment with diuretics and/or positive inotropic agents.
Time frame: Day 30, Day 60, Day 90 and Follow-up (30 days post-last dose, assessed up to Day 120)
Ratio of BNP at Specified Visits to BNP at Baseline
B-type natriuretic peptide (BNP) levels in the blood are used for screening, diagnosis of acute chronic heart failure (CHF) and may be useful to establish prognosis in heart failure.
Time frame: Day 30, Day 60, Day 90, Premature discontinuation (only for participants who have discontinued the study prematurely, to be performed as soon as possible after withdrawal of study drug) and Follow-up (30 days post-last dose, assessed up to Day 120)
Ratio of NT-proBNP at Specified Visits to NT-proBNP at Baseline
N-terminal pro-B type natriuretic peptide (NT-proBNP) levels in the blood are used for screening, diagnosis of acute chronic heart failure (CHF) and may be useful to establish prognosis in heart failure.
Time frame: Day 30, Day 60, Day 90, Premature discontinuation (only for participants who have discontinued the study prematurely, to be performed as soon as possible after withdrawal of study drug) and Follow-up (30 days post-last dose, assessed up to Day 120)
Change From Baseline in KCCQ Questionnaire Scores at Specified Visits
The Kansas City Cardiomyopathy Questionnaire (KCCQ) was the leading health related quality of life measure for subjects with CHF. KCCQ was a 23 item questionnaire that independently measures the impact of subjects HF, or its treatment, on 7 distinct domains: self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. KCCQ clinical summary score is a composite assessment of physical limitations and total symptom scores. Results from the total symptom summary score are presented. Scores are transformed to a range of 0-100, in which higher scores reflect better health status. In the below table, categorical data represents change from baseline data at respective time points.
Time frame: Baseline, Day 30 and Day 90
Change From Baseline in EQ-5D-3L Questionnaire Scores at Specified Visits
EuroQol Group 5-Dimension, 3-Level (EQ-5D-3L): participant rated questionnaire to assess health-related quality of life. It consists of EQ-5D descriptive system and EQ-5D Visual Analog Scale (VAS). EQ-5D-3L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems (1), some problems (2), and extreme problems (3). For this population, the possible EQ-5D-3L index scores ranges from -0.11 (that is, 3 for all 5 dimensions) to 1.0 (that is, 1 for all 5 dimensions), where higher scores indicate a better health state.
Time frame: Baseline, Day 30, Day 90, Premature discontinuation (only for participants who have discontinued the study prematurely, to be performed as soon as possible after withdrawal of study drug) and Follow-up (30 days post-last dose, assessed up to Day 120)
Change From Baseline in Serum Potassium at Specified Visits
Time frame: Baseline, Day 30, Day 60, Day 90 and Follow-up (30 days post-last dose, assessed up to Day 120)
Change From Baseline in Systolic Blood Pressure at Specified Visits
Time frame: Baseline,Day 7,14,30,60,90,Premature discontinuation (only for participants who have discontinued the study prematurely, to be performed as soon as possible after withdrawal of study drug) and Follow-up (30 days post-last dose, assessed up to Day 120)
Change From Baseline in Diastolic Blood Pressure at Specified Visits
Time frame: Baseline,Day 7,14,30,60,90,Premature discontinuation (only for participants who have discontinued the study prematurely, to be performed as soon as possible after withdrawal of study drug) and Follow-up (30 days post-last dose, assessed up to Day 120)
Change From Baseline in Heart Rate at Specified Visits
Time frame: Baseline,Day 7,14,30,60,90,Premature discontinuation (only for participants who have discontinued the study prematurely, to be performed as soon as possible after withdrawal of study drug) and Follow-up (30 days post-last dose, assessed up to Day 120)
Study was conducted in 168 study centers in 25 countries worldwide, from 17 June 2013 (first participant first visit) to 09 December 2014 (last participant last visit).
| Milestone | Eplerenone (INSPRA®) | Finerenone (BAY94-8862) 2.5-5 mg OD | Finerenone (BAY94-8862) 5-10 mg OD | Finerenone (BAY94-8862) 7.5-15 mg OD | Finerenone (BAY94-8862) 10-20 mg OD | Finerenone (BAY94-8862) 15-20 mg OD |
|---|---|---|---|---|---|---|
| Started | 224 | 173 | 165 | 169 | 170 | 165 |
| Participants received study treatment and valid for safety analysis set | 221 | 172 | 163 | 167 | 169 | 163 |
| Completed | 144 | 121 | 122 | 123 | 134 | 124 |
| Not completed | 80 | 52 | 43 | 46 | 36 | 41 |
| Withdrew: Progressive disease | 1 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Death | 7 | 9 | 4 | 2 | 1 | 6 |
| Withdrew: Physician decision | 2 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 33 | 22 | 26 | 25 | 18 | 21 |
| Withdrew: Protocol violation | 0 | 2 | 1 | 2 | 0 | 1 |
| Withdrew: Non-compliance | 1 | 2 | 0 | 1 | 0 | 0 |
| Withdrew: Logistical difficulties | 0 | 1 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 33 | 15 | 8 | 14 | 16 | 13 |
| Withdrew: Sponsor decision | 2 | 0 | 1 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 2 | 1 | 0 | 0 |
N-terminal pro-B type natriuretic peptide (NT-proBNP) levels in the blood are used for screening, diagnosis of acute and chronic heart failure (CHF) and may be useful to establish prognosis in heart failure.
| Percentage of participants | Eplerenone (INSPRA®) | Finerenone (BAY94-8862) 2.5-5 mg OD | Finerenone (BAY94-8862) 5-10 mg OD | Finerenone (BAY94-8862) 7.5-15 mg OD | Finerenone (BAY94-8862) 10-20 mg OD | Finerenone (BAY94-8862) 15-20 mg OD |
|---|---|---|---|---|---|---|
| Percentage of Participants With a Relative Decrease in NT-proBNP of More Than 30% From Baseline to Day 90 | 37.2 ± 31.6 | 30.9 ± 24.9 | 32.5 ± 26.3 | 37.3 ± 30.9 | 38.8 ± 32.3 | 34.2 ± 27.9 |
Death due to any cause include cardiovascular (CV) death and Non-CV death. Non-CV death was classified by 2 subcategories: non-malignant causes and malignant causes.
| Participants | Eplerenone (INSPRA®) | Finerenone (BAY94-8862) 2.5-5 mg OD | Finerenone (BAY94-8862) 5-10 mg OD | Finerenone (BAY94-8862) 7.5-15 mg OD | Finerenone (BAY94-8862) 10-20 mg OD | Finerenone (BAY94-8862) 15-20 mg OD |
|---|---|---|---|---|---|---|
| Day 30 | 6 | 5 | 1 | 1 | 0 | 2 |
| Day 60 | 7 | 7 | 3 | 2 | 0 | 4 |
| Day 90 | 9 | 10 | 4 | 4 | 1 | 5 |
| Follow-up | 15 | 16 | 7 | 11 | 2 | 8 |
Hospitalizations were defined as any unplanned admission to hospital, i.e. completion of hospital admission procedures and one overnight \[i.e. date change\] stay or until the death of subject occurred. Hospitalizations and deaths were classified by 2 primary categories: CV and non-CV. The pre-specified subcategories for CV hospitalizations were as follows: 1. Worsening heart failure, 2.Acute myocardial infarction, 3. Arrhythmia, 4.Transient ischemic attack and stroke, 5. Other CV hospitalizations.
| Participants | Eplerenone (INSPRA®) | Finerenone (BAY94-8862) 2.5-5 mg OD | Finerenone (BAY94-8862) 5-10 mg OD | Finerenone (BAY94-8862) 7.5-15 mg OD | Finerenone (BAY94-8862) 10-20 mg OD | Finerenone (BAY94-8862) 15-20 mg OD |
|---|---|---|---|---|---|---|
| Day 30 | 28 | 23 | 14 | 8 | 7 | 15 |
| Day 60 | 43 | 33 | 23 | 21 | 15 | 23 |
| Day 90 | 45 | 35 | 26 | 29 | 22 | 28 |
| Follow-up | 56 | 43 | 38 | 36 | 27 | 34 |
Emergency presentations for WCHF were defined as newly developing signs and symptoms of WCHF after start of treatment with study drug, requiring an additional emergency presentation to hospital and IV treatment with diuretics and/or positive inotropic agents.
| Participants | Eplerenone (INSPRA®) | Finerenone (BAY94-8862) 2.5-5 mg OD | Finerenone (BAY94-8862) 5-10 mg OD | Finerenone (BAY94-8862) 7.5-15 mg OD | Finerenone (BAY94-8862) 10-20 mg OD | Finerenone (BAY94-8862) 15-20 mg OD |
|---|---|---|---|---|---|---|
| Day 30 | 21 | 19 | 12 | 9 | 7 | 15 |
| Day 60 | 35 | 30 | 20 | 17 | 14 | 22 |
| Day 90 | 37 | 32 | 22 | 24 | 18 | 28 |
| Follow-up | 47 | 40 | 30 | 30 | 26 | 34 |
B-type natriuretic peptide (BNP) levels in the blood are used for screening, diagnosis of acute chronic heart failure (CHF) and may be useful to establish prognosis in heart failure.
| Ratio | Eplerenone (INSPRA®) | Finerenone (BAY94-8862) 2.5-5 mg OD | Finerenone (BAY94-8862) 5-10 mg OD | Finerenone (BAY94-8862) 7.5-15 mg OD | Finerenone (BAY94-8862) 10-20 mg OD | Finerenone (BAY94-8862) 15-20 mg OD |
|---|---|---|---|---|---|---|
| Day 30 | 0.925 ± 2.02 | 0.944 ± 1.952 | 0.878 ± 1.713 | 0.832 ± 1.959 | 0.852 ± 1.901 | 0.879 ± 1.968 |
| Day 60 | 0.783 ± 2.194 | 0.864 ± 2.139 | 0.854 ± 1.854 | 0.79 ± 2.179 | 0.711 ± 2.116 | 0.824 ± 2.142 |
| Day 90 | 0.723 ± 2.202 | 0.813 ± 2.412 | 0.839 ± 1.93 | 0.719 ± 2.204 | 0.706 ± 2.34 | 0.771 ± 2.197 |
| Premature discontinuation | 0.896 ± 0.896 | 1.104 ± 2.15 | 1.006 ± 2.422 | 0.884 ± 1.973 | 0.848 ± 2.218 | 1.044 ± 2.174 |
| Follow-up | 0.795 ± 2.232 | 0.815 ± 2.388 | 0.886 ± 2.199 | 0.726 ± 2.397 | 0.729 ± 2.487 | 0.852 ± 2.169 |
N-terminal pro-B type natriuretic peptide (NT-proBNP) levels in the blood are used for screening, diagnosis of acute chronic heart failure (CHF) and may be useful to establish prognosis in heart failure.
| Ratio | Eplerenone (INSPRA®) | Finerenone (BAY94-8862) 2.5-5 mg OD | Finerenone (BAY94-8862) 5-10 mg OD | Finerenone (BAY94-8862) 7.5-15 mg OD | Finerenone (BAY94-8862) 10-20 mg OD | Finerenone (BAY94-8862) 15-20 mg OD |
|---|---|---|---|---|---|---|
| Day 30 | 0.883 ± 2.458 | 0.98 ± 2.158 | 0.874 ± 2.14 | 0.888 ± 2.123 | 0.822 ± 2.217 | 0.921 ± 2.136 |
| Day 60 | 0.749 ± 2.73 | 0.822 ± 2.423 | 0.814 ± 2.178 | 0.81 ± 2.268 | 0.748 ± 2.496 | 0.829 ± 2.288 |
| Day 90 | 0.688 ± 2.59 | 0.789 ± 2.661 | 0.765 ± 2.214 | 0.783 ± 2.454 | 0.728 ± 2.795 | 0.771 ± 2.471 |
| Premature discontinuation | 0.948 ± 2.684 | 1.369 ± 2.087 | 1.267 ± 2.261 | 0.927 ± 1.864 | 1.133 ± 2.981 | 0.965 ± 2.352 |
| Follow-up | 0.747 ± 2.616 | 0.747 ± 2.741 | 0.887 ± 2.604 | 0.809 ± 2.647 | 0.746 ± 2.472 | 0.849 ± 2.348 |
The Kansas City Cardiomyopathy Questionnaire (KCCQ) was the leading health related quality of life measure for subjects with CHF. KCCQ was a 23 item questionnaire that independently measures the impact of subjects HF, or its treatment, on 7 distinct domains: self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. KCCQ clinical summary score is a composite assessment of physical limitations and total symptom scores. Results from the total symptom summary score are presented. Scores are transformed to a range of 0-100, in which higher scores reflect better health status. In the below table, categorical data represents change from baseline data at respective time points.
| Scores on a scale | Eplerenone (INSPRA®) | Finerenone (BAY94-8862) 2.5-5 mg OD | Finerenone (BAY94-8862) 5-10 mg OD | Finerenone (BAY94-8862) 7.5-15 mg OD | Finerenone (BAY94-8862) 10-20 mg OD | Finerenone (BAY94-8862) 15-20 mg OD |
|---|---|---|---|---|---|---|
| Baseline | 43.7 ± 23 | 42.8 ± 22.6 | 45.4 ± 24 | 42.1 ± 23.2 | 42.3 ± 23.7 | 43.2 ± 22.5 |
| Day 30 | 20.5 ± 26.2 | 18.2 ± 22.7 | 19.3 ± 26.5 | 23 ± 24.4 | 24.9 ± 22.9 | 20.6 ± 27 |
| Day 90 | 24.3 ± 27.6 | 21.3 ± 27.2 | 24.5 ± 27 | 29.3 ± 28.6 | 28.3 ± 23.8 | 22.2 ± 30.6 |
EuroQol Group 5-Dimension, 3-Level (EQ-5D-3L): participant rated questionnaire to assess health-related quality of life. It consists of EQ-5D descriptive system and EQ-5D Visual Analog Scale (VAS). EQ-5D-3L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems (1), some problems (2), and extreme problems (3). For this population, the possible EQ-5D-3L index scores ranges from -0.11 (that is, 3 for all 5 dimensions) to 1.0 (that is, 1 for all 5 dimensions), where higher scores indicate a better health state.
| Scores on scale | Eplerenone (INSPRA®) | Finerenone (BAY94-8862) 2.5-5 mg OD | Finerenone (BAY94-8862) 5-10 mg OD | Finerenone (BAY94-8862) 7.5-15 mg OD | Finerenone (BAY94-8862) 10-20 mg OD | Finerenone (BAY94-8862) 15-20 mg OD |
|---|---|---|---|---|---|---|
| Baseline | 0.58 ± 0.25 | 0.59 ± 0.25 | 0.62 ± 0.23 | 0.58 ± 0.23 | 0.56 ± 0.25 | 0.59 ± 0.24 |
| Day 30 | 0.06 ± 0.23 | 0.02 ± 0.24 | 0.02 ± 0.23 | 0.07 ± 0.22 | 0.06 ± 0.23 | 0.02 ± 0.25 |
| Day 90 | 0.08 ± 0.24 | 0.03 ± 0.27 | 0.04 ± 0.25 | 0.08 ± 0.2 | 0.1 ± 0.24 | 0.06 ± 0.28 |
| Premature discontinuation | -0.12 ± 0.25 | -0.06 ± 0.29 | -0.09 ± 0.24 | -0.1 ± 0.24 | -0.05 ± 0.25 | 0 ± 0.29 |
| Follow-up | 0.06 ± 0.26 | 0.01 ± 0.25 | 0.01 ± 0.27 | 0.08 ± 0.23 | 0.07 ± 0.23 | 0.04 ± 0.28 |
| millimoles per liter (mmol/L) | Eplerenone (INSPRA®) | Finerenone (BAY94-8862) 2.5-5 mg OD | Finerenone (BAY94-8862) 5-10 mg OD | Finerenone (BAY94-8862) 7.5-15 mg OD | Finerenone (BAY94-8862) 10-20 mg OD | Finerenone (BAY94-8862) 15-20 mg OD |
|---|---|---|---|---|---|---|
| Baseline | 4.159 ± 0.495 | 4.081 ± 0.501 | 4.211 ± 0.541 | 4.174 ± 0.443 | 4.131 ± 0.506 | 4.117 ± 0.506 |
| Day 30 | 0.057 ± 0.608 | 0.135 ± 0.573 | 0.075 ± 0.523 | 0.085 ± 0.475 | 0.21 ± 0.592 | 0.193 ± 0.556 |
| Day 60 | 0.179 ± 0.589 | 0.091 ± 0.568 | 0.131 ± 0.566 | 0.171 ± 0.54 | 0.274 ± 0.522 | 0.216 ± 0.547 |
| Day 90 | 0.307 ± 0.609 | 0.184 ± 0.574 | 0.153 ± 0.516 | 0.164 ± 0.579 | 0.275 ± 0.58 | 0.245 ± 0.574 |
| Follow-up | 0.117 ± 0.621 | 0.226 ± 0.694 | 0.054 ± 0.623 | 0.05 ± 0.572 | 0.175 ± 0.559 | 0.036 ± 0.556 |
| millimeter of mercury (mmHg) | Eplerenone (INSPRA®) | Finerenone (BAY94-8862) 2.5-5 mg OD | Finerenone (BAY94-8862) 5-10 mg OD | Finerenone (BAY94-8862) 7.5-15 mg OD | Finerenone (BAY94-8862) 10-20 mg OD | Finerenone (BAY94-8862) 15-20 mg OD |
|---|---|---|---|---|---|---|
| Baseline | 120.554 ± 18.706 | 119.492 ± 16.348 | 118.498 ± 14.355 | 119.087 ± 16.677 | 116.024 ± 16.895 | 116.941 ± 16.548 |
| Day 7 | -0.541 ± 13.894 | -3.178 ± 13.72 | -2.565 ± 12.278 | 0.568 ± 12.733 | 0.162 ± 15.416 | -0.546 ± 13.498 |
| Day 14 | -3.442 ± 14.258 | -4.488 ± 10.31 | 4.142 ± 15.001 | 1.241 ± 13.561 | -3.099 ± 12.591 | -2.906 ± 15.406 |
| Day 30 | 0.067 ± 15.312 | -0.824 ± 15.747 | -0.367 ± 14.984 | 0.374 ± 14.433 | 1.786 ± 15.039 | 0.899 ± 14.608 |
| Day 60 | 0.684 ± 16.315 | 0.337 ± 14.176 | -1.249 ± 13.659 | -1.811 ± 14.462 | 0.981 ± 15.525 | 0.667 ± 14.83 |
| Day 90 | -0.967 ± 16.408 | 0.922 ± 15.847 | 0.047 ± 15.643 | -0.664 ± 15.018 | 1.216 ± 17.831 | 0.956 ± 15.743 |
| Premature discontinuation | -2.991 ± 16.456 | -0.41 ± 13.936 | -2.167 ± 19.963 | 9.391 ± 22.378 | -2.32 ± 11.963 | -0.028 ± 15.42 |
| Follow-up | 0.188 ± 16.751 | 2.869 ± 15.502 | 1.95 ± 16.148 | -0.928 ± 17.953 | 2.041 ± 16.189 | 3.037 ± 16.782 |
| millimeter for mercury (mmHg) | Eplerenone (INSPRA®) | Finerenone (BAY94-8862) 2.5-5 mg OD | Finerenone (BAY94-8862) 5-10 mg OD | Finerenone (BAY94-8862) 7.5-15 mg OD | Finerenone (BAY94-8862) 10-20 mg OD | Finerenone (BAY94-8862) 15-20 mg OD |
|---|---|---|---|---|---|---|
| Baseline | 71.633 ± 11.647 | 71.044 ± 10.762 | 71.442 ± 8.508 | 70.61 ± 9.692 | 70.343 ± 10.394 | 71.145 ± 9.809 |
| Day 7 | -1.351 ± 10.237 | -1.693 ± 9.911 | -2.143 ± 9.848 | 0.013 ± 9.733 | -0.738 ± 10.534 | -1.166 ± 8.964 |
| Day 14 | -3.442 ± 10.089 | -0.537 ± 9.59 | 1.608 ± 9.423 | -0.083 ± 7.421 | -2.387 ± 10.51 | -0.625 ± 9.41 |
| Day 30 | -0.503 ± 10.826 | 0.146 ± 10.667 | -0.845 ± 8.91 | -0.068 ± 9.633 | -0.094 ± 10.086 | -1.163 ± 9.622 |
| Day 60 | -0.613 ± 11.096 | -0.199 ± 11.297 | -2.144 ± 9.552 | -0.85 ± 10.472 | 0.17 ± 10.312 | -0.575 ± 10.427 |
| Day 90 | -0.716 ± 11.035 | -0.106 ± 11.148 | -1.738 ± 9.015 | -1.121 ± 9.96 | -0.545 ± 11.212 | -0.877 ± 11.327 |
| Premature discontinuation | -3.185 ± 11.853 | 0.868 ± 9.239 | -2.194 ± 15.522 | 4.101 ± 12.151 | -2.96 ± 9.199 | -0.083 ± 10.113 |
| Follow-up | -1.218 ± 11.477 | 0.696 ± 13.172 | -0.444 ± 10.197 | -1.16 ± 11.114 | -0.298 ± 11.521 | -0.172 ± 10.211 |
| Beats per minute (Beats/min) | Eplerenone (INSPRA®) | Finerenone (BAY94-8862) 2.5-5 mg OD | Finerenone (BAY94-8862) 5-10 mg OD | Finerenone (BAY94-8862) 7.5-15 mg OD | Finerenone (BAY94-8862) 10-20 mg OD | Finerenone (BAY94-8862) 15-20 mg OD |
|---|---|---|---|---|---|---|
| Baseline | 74.957 ± 13.813 | 73.369 ± 13.396 | 72.681 ± 12.623 | 74.184 ± 12.369 | 73.852 ± 11.999 | 74.329 ± 13.187 |
| Day 7 | -0.8 ± 10.751 | 1.073 ± 13.5 | -0.63 ± 11.696 | -0.719 ± 10.77 | -0.548 ± 11.144 | -1.176 ± 13.398 |
| Day 14 | -3.109 ± 15.101 | 0.599 ± 16.387 | 1.842 ± 14.988 | -1.324 ± 13.666 | 0.423 ± 11.247 | -3.969 ± 13.715 |
| Day 30 | 0.294 ± 13.61 | 1.064 ± 14.128 | 0.435 ± 13.63 | -0.349 ± 12.636 | -0.802 ± 11.311 | -1.633 ± 12.719 |
| Day 60 | 0.297 ± 13.033 | -0.975 ± 14.953 | -1.741 ± 10.86 | -2.318 ± 14.225 | 0.192 ± 13.377 | -1.608 ± 13.828 |
| Day 90 | -0.189 ± 12.289 | -1.647 ± 13.001 | -2.89 ± 12.034 | -2.212 ± 12.041 | -0.71 ± 13.777 | -1.145 ± 14.284 |
| Premature discontinuation | -2.278 ± 15.909 | -1.424 ± 15.587 | -0.222 ± 7.591 | 1.101 ± 10.22 | 4.733 ± 13.646 | -2.072 ± 19.731 |
| Follow-up | -1.281 ± 13.789 | -2.057 ± 13.982 | -0.626 ± 14.196 | -1.326 ± 15.488 | 0.834 ± 14.159 | -1.317 ± 14.636 |
Collected over Adverse events: from the start of study treatment until 3 days post-last dose, up to approximately 93 days. All Cause Mortality: assessed until 30 days post-last dose, up to approximately 120 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Eplerenone (INSPRA®) | 19/221 (8.6%) | 77/221 (34.8%) | 85/221 (38.5%) |
| Finerenone(BAY94-8862) 2.5-5 mg OD | 17/172 (9.9%) | 72/172 (41.9%) | 63/172 (36.6%) |
| Finerenone (BAY94-8862) 5-10 mg OD | 9/163 (5.5%) | 47/163 (28.8%) | 59/163 (36.2%) |
| Finerenone (BAY94-8862) 7.5-15 mg OD | 12/167 (7.2%) | 52/167 (31.1%) | 50/167 (29.9%) |
| Finerenone (BAY94-8862) 10-20 mg OD | 2/169 (1.2%) | 46/169 (27.2%) | 50/169 (29.6%) |
| Finerenone (BAY94-8862) 15-20 mg OD | 9/163 (5.5%) | 57/163 (35%) | 65/163 (39.9%) |
| Event | Eplerenone (INSPRA®) | Finerenone(BAY94-8862) 2.5-5 mg OD | Finerenone (BAY94-8862) 5-10 mg OD | Finerenone (BAY94-8862) 7.5-15 mg OD | Finerenone (BAY94-8862) 10-20 mg OD | Finerenone (BAY94-8862) 15-20 mg OD |
|---|---|---|---|---|---|---|
| Cardiac failureCardiac disorders | 21/221 | 16/172 | 15/163 | 21/167 | 11/169 | 13/163 |
| Cardiac failure chronicCardiac disorders | 13/221 | 9/172 | 7/163 | 8/167 | 6/169 | 12/163 |
| HyperkalaemiaMetabolism and nutrition disorders | 5/221 | 6/172 | 4/163 | 7/167 | 5/169 | 6/163 |
| Cardiac failure acuteCardiac disorders | 6/221 | 6/172 | 3/163 | 1/167 | 3/169 | 5/163 |
| Cardiac failure congestiveCardiac disorders | 4/221 | 5/172 | 2/163 | 2/167 | 0/169 | 3/163 |
| Renal failure acuteRenal and urinary disorders | 0/221 | 5/172 | 1/163 | 4/167 | 2/169 | 1/163 |
| Ventricular tachycardiaCardiac disorders | 2/221 | 4/172 | 0/163 | 3/167 | 1/169 | 1/163 |
| PneumoniaInfections and infestations | 1/221 | 3/172 | 3/163 | 1/167 | 2/169 | 3/163 |
| Renal failure chronicRenal and urinary disorders | 0/221 | 0/172 | 1/163 | 2/167 | 0/169 | 3/163 |
| Ventricular fibrillationCardiac disorders | 3/221 | 3/172 | 0/163 | 0/167 | 0/169 | 0/163 |
| Event | Eplerenone (INSPRA®) | Finerenone(BAY94-8862) 2.5-5 mg OD | Finerenone (BAY94-8862) 5-10 mg OD | Finerenone (BAY94-8862) 7.5-15 mg OD | Finerenone (BAY94-8862) 10-20 mg OD | Finerenone (BAY94-8862) 15-20 mg OD |
|---|---|---|---|---|---|---|
| HypokalaemiaMetabolism and nutrition disorders | 34/221 | 20/172 | 21/163 | 15/167 | 14/169 | 17/163 |
| Cardiac failureCardiac disorders | 13/221 | 14/172 | 10/163 | 5/167 | 7/169 | 10/163 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 11/221 | 12/172 | 7/163 | 6/167 | 3/169 | 10/163 |
| HypotensionVascular disorders | 11/221 | 7/172 | 11/163 | 11/167 | 7/169 | 8/163 |
| DiarrhoeaGastrointestinal disorders | 8/221 | 6/172 | 6/163 | 10/167 | 6/169 | 7/163 |
| HyperkalaemiaMetabolism and nutrition disorders | 8/221 | 5/172 | 7/163 | 7/167 | 6/169 | 9/163 |
| Renal impairmentRenal and urinary disorders | 8/221 | 6/172 | 7/163 | 6/167 | 8/169 | 9/163 |
| Blood creatinine increasedInvestigations | 12/221 | 5/172 | 7/163 | 3/167 | 4/169 | 8/163 |
| DizzinessNervous system disorders | 12/221 | 8/172 | 6/163 | 6/167 | 7/169 | 6/163 |
| NauseaGastrointestinal disorders | 7/221 | 9/172 | 2/163 | 5/167 | 2/169 | 6/163 |
Safety analysis set (SAF): all randomized participants who took at least one dose of study drug and with data after beginning of treatment.
| Age, Continuous(years) | Eplerenone (INSPRA®) | Finerenone (BAY94-8862) 2.5-5 mg OD | Finerenone (BAY94-8862) 5-10 mg OD | Finerenone (BAY94-8862) 7.5-15 mg OD | Finerenone (BAY94-8862) 10-20 mg OD | Finerenone (BAY94-8862) 15-20 mg OD | Total |
|---|---|---|---|---|---|---|---|
| Mean | 72.38 ± 9.92 | 72.53 ± 9.74 | 71.81 ± 10.55 | 69.27 ± 9.83 | 71.27 ± 10.27 | 69.2 ± 10.15 | 71.15 ± 10.14 |
| Sex: Female, Male(Participants) | Eplerenone (INSPRA®) | Finerenone (BAY94-8862) 2.5-5 mg OD | Finerenone (BAY94-8862) 5-10 mg OD | Finerenone (BAY94-8862) 7.5-15 mg OD | Finerenone (BAY94-8862) 10-20 mg OD | Finerenone (BAY94-8862) 15-20 mg OD | Total |
|---|---|---|---|---|---|---|---|
| Female | 51 | 37 | 37 | 43 | 41 | 31 | 240 |
| Male | 170 | 135 | 126 | 124 | 128 | 132 | 815 |
| Baseline BNP(pg/ml) | Eplerenone (INSPRA®) | Finerenone (BAY94-8862) 2.5-5 mg OD | Finerenone (BAY94-8862) 5-10 mg OD | Finerenone (BAY94-8862) 7.5-15 mg OD | Finerenone (BAY94-8862) 10-20 mg OD | Finerenone (BAY94-8862) 15-20 mg OD | Total |
|---|---|---|---|---|---|---|---|
| Geometric mean | 594.290 ± 2.601 | 677.906 ± 2.637 | 574.245 ± 2.543 | 570.776 ± 2.741 | 606.080 ± 2.598 | 552.032 ± 2.698 | 594.732 ± 2.634 |
| Baseline NT-proBNP(pg/ml) | Eplerenone (INSPRA®) | Finerenone (BAY94-8862) 2.5-5 mg OD | Finerenone (BAY94-8862) 5-10 mg OD | Finerenone (BAY94-8862) 7.5-15 mg OD | Finerenone (BAY94-8862) 10-20 mg OD | Finerenone (BAY94-8862) 15-20 mg OD | Total |
|---|---|---|---|---|---|---|---|
| Geometric mean | 4730.170 ± 2.938 | 4793.430 ± 3.084 | 4184.631 ± 3.093 | 3776.859 ± 3.395 | 4163.898 ± 2.734 | 3791.677 ± 3.013 | 4246.883 ± 3.040 |
Showing the first 100 of 172 sites across 25 countries. Choose a country and city above to see the rest.
Ran from Jun 2013 to primary completion in Nov 2014, 16 months.
Results were first posted in Jun 2021, 6 years 7 months after primary completion. A results delay was requested in Jun 2015.
Of 73 industry-sponsored phase 2 interventional studies under Heart Failure, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 31. This study's 16 months is below that.
Counting every sponsor, half of 184 studies reached it within 29 months; a quarter within 17 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Finerenone